Sanofi recently abandoned its proposal to license Maze's developmental drug to treat Pompe disease in the face of the FTC's decision to seek a preliminary injunction to block the deal. This move highlights the agency's commitment to closely scrutinizing nascent competition in life science and pharma deals. The panel will discuss the implications of the FTC's challenge.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.
